| SAITAMA MEDICAL UNIVERSITY Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129880 | METHOD FOR DETERMINING SENSITIVITY TO IRINOTECAN AND USE THEREOF - To provide a method for determining the sensitivity of a patient to irinotecan, SN-38, and/or a salt thereof, which method can determine the therapeutic response of the patient and to provide a novel cancer therapeutic means employing the method. | 05-24-2012 |
| 20110262529 | CYTOTOXIC T CELL EPITOPE PEPTIDE FOR SARS CORONAVIRUS, AND USE THEREOF - The present invention aims to provide a novel CTL epitope peptide of the SARS coronavirus. The present invention provides a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12, 13, 15, 17, 18, 23 and 24. | 10-27-2011 |
| 20110091886 | METHOD OF DISTINGUISHING INFLAMMATORY PATHOGEN CAUSING ACUTE RESPIRATORY INFECTION - Disclosed is a method of distinguishing an inflammatory pathogen causing acute respiratory infection wherein the pathogen to be distinguished is a pathogen residing in the respiratory tract, which comprises: (a) a step for counting gene copies originating in subject cells in DNA prepared from a specimen containing secretion from the respiratory tract of the subject; (b) a step for counting the gene copies originating in the pathogen in the DNA; (c) a step for calculating the relative value of count of the gene copies originating in the pathogen to the count of the gene copies originating in the subject cells; and (d) a step for distinguishing whether the pathogen is an inflammatory pathogen causing the disease or not based on the distinguishing standard and the relative value. | 04-21-2011 |
| 20110081717 | DOUBLE-STRANDED NUCLEIC ACID MOLECULE, CANCER CELL PROLIFERATION INHIBITOR AND PHARMACEUTICAL AGENT SUITABLE FOR PREVENTION OR TREATMENT OF CANCER - A double-stranded nucleic acid molecule including (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 21, and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a), wherein the double-stranded nucleic acid molecule is for suppressing the expression of at least one of APP and EBAG9 genes. | 04-07-2011 |
| 20100173405 | Double-Stranded Nucleic Acid Molecule Cancer Cell Proliferation Inhibitor and Pharmaceutical Agent Suitable for Prevention or Treatment of Uterine Cancer, Breast Cancer, and Bladder Cancer - A double-stranded nucleic acid molecule for suppressing the expression of at least one of COX7RP and Efp genes which includes (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 38 and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a); a cancer cell proliferation inhibitor with the double-stranded nucleic acid molecule and against at least one of uterine, breast and bladder cancer cells; and a pharmaceutical agent with the cancer cell proliferation inhibitor and against at least one of uterine, breast and bladder cancers. | 07-08-2010 |
| 20100136098 | AVIAN INFLUENZA VACCINE - The present invention provides an avian influenza vaccine containing a peptide-bound liposome wherein;
| 06-03-2010 |
| 20090155782 | Homoeologous Region Determining Method by Homo Junction Fingerprint Method, Homoeologous Region Determining Device, and Gene Screening Method - To provide a method for efficiently searching for a recessive disease gene without needing any pedigree analysis. In a homoeologous region determining method, the following steps are conducted. It is determined whether or not the base constituting a polymorphic marker of a sample DNA of diploid or higher polyploidy is a homojunction. Homojunction region information representing the region of the sample DNA where polymorphic markers determined as continuous homojunctions acquired. If the continuous probability and/or continuous distance of the polymorphic markers contained in the homojunction region information satisfy a predetermined determination condition, the homojunction region is determined as a homoeologous region. A homoeologous region determining device and a gene screening method for identifying a disease susceptibility gene from the determined homoeologous region are also provided. | 06-18-2009 |
